Fluicell AB is a Sweden-based company within healthcare industry. It commercializes a product portfolio for processing and studying of individual cells, primarily in the field of drug development. The Companyâ€™s products comprise research tools BioPen and Dynaflow Resolve. Tools enable researchers to study, process and measure drug impact on individual cells. Also, the Company develops bioprinting technology Biopixlar Retina in both two-dimensional (2D) and three-dimensional (3D) options. Biopixlar Retina creates complex tissue-like structures with control over positioning of individual cells.

Employees

Sector

Biotechnology & Medical Research

Calendar

11-12 Earnings release - Q3 2026

More about the company

Quotes

Date	Price	Change	Volume
26-10-30	SEK 27.90	+0.72%	286
26-10-29	SEK 27.70	-0.36%	3,393
26-10-28	SEK 27.80	+2.21%	3,443
26-10-27	SEK 27.20	-1.09%	925
26-10-26	SEK 27.50	+1.10%	871

Delayed Quote Nasdaq Stockholm

More quotes

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

Market Closed - Nasdaq Stockholm 08:30:00 2026-10-30 EDT			5-day change	1st Jan Change
27.90 ^SEK	+0.72%		+2.57%	+179.00%

09-15	Fluicell: Delayed €0.5m receivable settled	FW
08-28	Fluicell AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI

Market Cap	38.33M 3.9M 3.49M 3.21M 2.91M 5.44M 370M 5.55M 15.39M 195M 14.64M 14.33M 615M	P/E 2024	-1.1x	P/E 2025	-1.65x
Enterprise Value	36.06M 3.67M 3.29M 3.02M 2.74M 5.12M 349M 5.22M 14.48M 183M 13.78M 13.48M 578M	EV / Sales 2024	2.04x	EV / Sales 2025	1.91x
Free-Float	78.85%	Yield 2024 *	-	Yield 2025	-

Markets		Quality
Nasdaq Stockholm	FLUI	Delayed
Deutsche Boerse AG	5J90	Delayed
Boerse Muenchen	5J90	Real-time
Börse Stuttgart	5J90	Delayed

09-15	Fluicell: Delayed €0.5m receivable settled	FW
08-28	Fluicell AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-28	Fluicell increases revenue and turns to operating profit	FW
05-08	Fluicell reports sharp revenue surge and swings to profit in the first quarter	FW
05-08	Fluicell Q1 net sales up at SEK 6.1 million	RE
05-08	Fluicell AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-07	Fluicell nominates AstraZeneca executive to Board of Directors	FW
04-30	Committee proposes Niklas Frisk as Fluicell chairman	RE
04-30	Fluicell proposes new Board of Directors	FW
02-20	Fluicell Narrows Operating Loss in Q4, Final Report Confirms	FW
02-20	Fluicell Q4 net sales SEK 3.8 mln	RE
02-20	Fluicell AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
02-11	Fluicell gets EPO approval for microfluidics patent	RE

Fluicell AB Stock

Stocks

FLUI

SE0023595459

Biotechnology & Medical Research

Valuation: Fluicell AB

Chart: Fluicell AB

Latest news: Fluicell AB

Press Releases: Fluicell AB

Quotes and Performance

Price Extremes

Managers and Directors: Fluicell AB

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

10-14	Fluicell : at Breakthrough T1D Clinical & Research Congress	PU
25-09-02	Fluicell : and Ambusol enter into exclusive global license and development agreement regarding technology for cancer treatment	PU
25-08-22	Fluicell : receives funding from Breakthrough T1D for collaboration with leading medical university to develop tissue-based type 1 diabetes therapeutics	PU
21-09-29	BioStock: Fluicell partners with big pharma for 3-D bioprinting project	AQ
21-07-01	BioStock: 2021 represents beginning of new era for Fluicell	AQ

1 day	+0.72%
1 week	+2.57%
1 month	-4.78%
3 months	-10.29%
6 months	+95.79%
Current year	+179.00%

1 week	26.3	28.9
1 month	25.3	31.9
Current year	7.65	67.2
1 year	7.65	67.2
3 years	7.45	433.3
5 years	7.45	10,097.5
10 years	7.45	15,330

Manager	Title	Age	Since
Carolina Trkulja CEO	Chief Executive Officer	42	2022-12-31
Gavin Jeffries CTO	Chief Tech/Sci/R&D Officer	46	2016-12-31
Niklas Joakim Wahlberg DFI	Director of Finance/CFO	56	2023-06-30

Director	Title	Age	Since
Daniel T. Chiu BRD	Director/Board Member	54	2016-12-31
Carl Fhager BRD	Director/Board Member	51	2016-12-31
Jan Orwar BRD	Director/Board Member	62	2014-12-31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
FLUICELL AB	+0.72%	+2.57%	+112.98%	-92.82%	3.9M
WUXI APPTEC CO., LTD.	-0.62%	-1.87%	+42.87%	+64.15%	63.77B
ARGENX SE	+0.35%	+3.20%	+14.40%	+81.76%	56.37B
LONZA GROUP AG	+0.53%	+1.96%	+16.24%	+103.35%	54.62B
IQVIA HOLDINGS INC.	-2.81%	-4.31%	+23.50%	+47.83%	44.06B
BEONE MEDICINES AG	-0.33%	-1.93%	+19.28%	+98.80%	42.11B
REVOLUTION MEDICINES, INC.	+0.55%	+2.31%	+225.14%	+866.21%	41B
GENMAB A/S	+3.27%	+47.96%	+112.84%	+96.58%	34.92B
CELLTRION, INC.	+1.22%	-1.44%	+14.57%	+46.95%	32.82B
INSMED INCORPORATED	+0.89%	+20.55%	-40.62%	+349.24%	24.7B
Average	+0.38%	+7.04%	+54.12%	+166.21%	39.43B
Weighted average by Cap.	+0.18%	+5.44%	+47.99%	+176.67%

	2024	2025
Net sales	1.86M 189K 169K 156K 141K 264K 17.97M 269K 746K 9.45M 710K 695K 29.81M	6M 611K 547K 503K 456K 852K 58.01M 868K 2.41M 30.51M 2.29M 2.24M 96.23M
Net income	-15.51M -1.58M -1.41M -1.3M -1.18M -2.2M -150M -2.24M -6.23M -78.86M -5.93M -5.8M -249M	-8.33M -848K -760K -699K -633K -1.18M -80.53M -1.21M -3.34M -42.36M -3.18M -3.12M -134M
Net Debt	-15.92M -1.62M -1.45M -1.34M -1.21M -2.26M -154M -2.3M -6.39M -80.96M -6.08M -5.95M -255M	-2.26M -230K -206K -190K -172K -321K -21.86M -327K -908K -11.5M -864K -846K -36.27M